NCT01705184 - Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer. | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

October 31, 2017

Conditions

Non-small Cell Lung Cancer MetastaticNonsquamous Nonsmall Cell Neoplasm of Lung

Interventions

DRUG

Cisplatin

75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence

DRUG

Bevacizumab

7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence

DRUG

Pemetrexed

500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.

Trial Locations (12)

Caen - Centre François Baclesse, Caen

Caen - CHU Côte de Nacre, Caen

Rennes - CHU, Rennes

Nantes - Centre René Gauducheau, Nantes

Strasbourg - NHC, Strasbourg

Mulhouse - CH, Mulhouse

HCL - Lyon Sud (Pneumologie), Pierre-Bénite

Hopital Tenon - Pneumologie, Paris

Avignon - Institut Sainte-Catherine, Avignon

Centre Hospitalier, Chauny

CH du Mans, Le Mans

Hôpital Nord - Oncologie Multidisciplinaire & Innovations Thérapeutiques, Marseille

All Listed Sponsors

lead

Intergroupe Francophone de Cancerologie Thoracique

OTHER